Bank of America maintains a 'buy' rating on Merck, anticipating a potential share re-rating driven by upcoming clinical trial data in oncology and other pipeline areas over the next 12 to 18 months. Key focus includes Phase 3 results for SAC-TMT in lung cancer and data on intismeran, a personalized cancer vaccine developed with Moderna, with important presentations expected at the European Society for Medical Oncology meeting. Merck's management is confident in the pipeline's potential, including new programs in ophthalmology and treatments targeting unmet medical needs, supporting the positive investment outlook.
As of Sep 24, 2026 01:41 WIB, Merck & Co., Inc. (MRK) trades at USD 147.56 on Pluang, showing a 1-day decline of 2.23%. The stock sees a strong buying interest with 73% of order activity on the platform favoring buys over sells. Despite the recent dip, the company maintains a substantial market cap of $372.32 billion, highlighting its significant presence in the health sector.
Amgen and Merck both offer dividends around 2.3%, but Amgen's dividend is more secure and has better growth prospects. Amgen covers its dividend with less than half of its earnings and has a strong cash flow and growth in key products, while Merck's ...
Stocks showed a split reaction Thursday as the Dow and S&P 500 rose with buyers favoring non-tech sectors, while the Nasdaq struggled due to ongoing pressure on AI and memory-chip stocks. The Producer Price Index (PPI) came in hotter than expected, r...
